Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma
Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have shown some promise in thoracic cancers, although efficacy is limited only to patie...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2019.00221/full |
id |
doaj-5d2cd58bc3794ae79b2caa39d7a20406 |
---|---|
record_format |
Article |
spelling |
doaj-5d2cd58bc3794ae79b2caa39d7a204062020-11-25T01:15:07ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2019-10-01710.3389/fcell.2019.00221487339Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and MesotheliomaThomas G. Johnson0Thomas G. Johnson1Thomas G. Johnson2Thomas G. Johnson3Karin Schelch4Sunali Mehta5Sunali Mehta6Andrew Burgess7Andrew Burgess8Glen Reid9Glen Reid10Asbestos Diseases Research Institute, Sydney, NSW, AustraliaCell Division Laboratory, The ANZAC Research Institute, Sydney, NSW, AustraliaSchool of Medicine, The University of Sydney, Sydney, NSW, AustraliaSydney Catalyst Translational Cancer Research Centre, The University of Sydney, Sydney, NSW, AustraliaInstitute of Cancer Research, Medical University of Vienna, Vienna, AustriaDepartment of Pathology, University of Otago, Dunedin, New ZealandMaurice Wilkins Centre, University of Otago, Dunedin, New ZealandCell Division Laboratory, The ANZAC Research Institute, Sydney, NSW, AustraliaSchool of Medicine, The University of Sydney, Sydney, NSW, AustraliaDepartment of Pathology, University of Otago, Dunedin, New ZealandMaurice Wilkins Centre, University of Otago, Dunedin, New ZealandLung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have shown some promise in thoracic cancers, although efficacy is limited only to patients harboring specific mutations or target expression. Although a number of actionable mutations have now been identified, a large population of thoracic cancer patients have no therapeutic options outside of first-line chemotherapy. It is therefore crucial to identify alternative targets that might lead to the development of new ways of treating patients diagnosed with these diseases. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) could serve as one such target. Recent studies also link this protein to many inherent behaviors of thoracic cancer cells such as proliferation, invasion, metastasis and involvement in cancer stem-like cells. Here, we review the regulation of YB-1 at the transcriptional, translational, post-translational and sub-cellular levels in thoracic cancer and discuss its potential use as a biomarker and therapeutic target.https://www.frontiersin.org/article/10.3389/fcell.2019.00221/fulllung cancermesotheliomatargeted therapybiomarkerY-box binding protein-1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Karin Schelch Sunali Mehta Sunali Mehta Andrew Burgess Andrew Burgess Glen Reid Glen Reid |
spellingShingle |
Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Karin Schelch Sunali Mehta Sunali Mehta Andrew Burgess Andrew Burgess Glen Reid Glen Reid Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma Frontiers in Cell and Developmental Biology lung cancer mesothelioma targeted therapy biomarker Y-box binding protein-1 |
author_facet |
Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Thomas G. Johnson Karin Schelch Sunali Mehta Sunali Mehta Andrew Burgess Andrew Burgess Glen Reid Glen Reid |
author_sort |
Thomas G. Johnson |
title |
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma |
title_short |
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma |
title_full |
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma |
title_fullStr |
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma |
title_full_unstemmed |
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma |
title_sort |
why be one protein when you can affect many? the multiple roles of yb-1 in lung cancer and mesothelioma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cell and Developmental Biology |
issn |
2296-634X |
publishDate |
2019-10-01 |
description |
Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have shown some promise in thoracic cancers, although efficacy is limited only to patients harboring specific mutations or target expression. Although a number of actionable mutations have now been identified, a large population of thoracic cancer patients have no therapeutic options outside of first-line chemotherapy. It is therefore crucial to identify alternative targets that might lead to the development of new ways of treating patients diagnosed with these diseases. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) could serve as one such target. Recent studies also link this protein to many inherent behaviors of thoracic cancer cells such as proliferation, invasion, metastasis and involvement in cancer stem-like cells. Here, we review the regulation of YB-1 at the transcriptional, translational, post-translational and sub-cellular levels in thoracic cancer and discuss its potential use as a biomarker and therapeutic target. |
topic |
lung cancer mesothelioma targeted therapy biomarker Y-box binding protein-1 |
url |
https://www.frontiersin.org/article/10.3389/fcell.2019.00221/full |
work_keys_str_mv |
AT thomasgjohnson whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT thomasgjohnson whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT thomasgjohnson whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT thomasgjohnson whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT karinschelch whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT sunalimehta whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT sunalimehta whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT andrewburgess whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT andrewburgess whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT glenreid whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma AT glenreid whybeoneproteinwhenyoucanaffectmanythemultiplerolesofyb1inlungcancerandmesothelioma |
_version_ |
1725154332885647360 |